Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese patients with an autoimmune condition that causes joint pain more than Taltz did alone.
The data suggest the GLP-1 drug Zepbound, which has already been shown to help with obesity and sleep apnea, among other conditions, may also be helpful for psoriatic arthritis, or PsA.
But it’s not clear if these results will have a significant impact on prescribing patterns for Lilly’s drugs, given that there’s already huge demand for Zepbound due to its significant weight loss effects.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
